Skip to main content

Table 2 Timing of Immune-Related Adverse Events with Relation to IL-2 Treatment

From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

  irAEs/Total Patients (%) Prior to IL-2 During IL-2 After IL-2
Total 152/1535 (8.4%) 31 24 97
mM 99/623 (16%) 16 12 71
mRCC 53/920 (5.8%) 15 12 26
Total irAEs   31 24 97
Related to IL-2   NA During and after IL-2 74
Undetermined if Related to IL2 or CPI   NA   15
Related to CPI   NA   24
  1. mM metastatic melanoma, mRCC metastatic renal cell cancer, irAEs immune-related adverse events, IL-2 interleukin-2, CPI checkpoint inhibitor, NA - not applicable